InMed's Michael
Woudenberg, Karen Long &
Prof. Mauro Maccarrone among Expert
Speakers
VANCOUVER, BC, Jan. 19, 2021 /PRNewswire/ - InMed
Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM)
(TSX:IN), a clinical-stage pharmaceutical company developing
medications targeting diseases with high unmet medical need and
leading the clinical development of cannabinol ("CBN"), today
announced that executives of the Company will speak at the 2021
Cannabinoid-Derived Pharmaceuticals Industry Review Summit
Europe ("CDP Europe"). CDP Europe will be held virtually from
January 19-21, 2021. Michael Woudenberg - Vice President, Chemistry,
Manufacturing & Controls, Karen
Long - Senior Director, Drug Development, and Prof. Mauro
Maccarrone PhD - Scientific Advisor to InMed will all be featured
as expert speakers at the event.
Mr. Michael Woudenberg will
participate on a panel discussion on the topic of "Comparing
Whole Plant & Synthetic Cannabinoids & Their Potential in
Pharmaceuticals" which will cover topics including the
availability of cannabinoids in both whole plant and synthetic
systems, the biggest trade-off between plant-derived and synthetic
compounds and comparing cost advantages in the short and long
term.
Ms. Karen Long will participate
on a panel discussion on the topic of "The Industry
Approach to Gaining Drug Approval" to compare the differences
in gaining drug approval around the world including a discussion of
case studies.
In addition, Prof. Mauro
Maccarrone, a member of InMed's Scientific Advisory Board
and Professor and Chair of Biochemistry, Department of
Biotechnological and Applied Clinical Sciences, University of
L'Aquila, Italy, will speak on the
complexity of the endocannabinoid system while discussing the
critical issues around endocannabinoid signaling regulation in a
lecture entitled "Plant-Derived & Endogenous Cannabinoids:
Naturally Different".
"We are grateful for the opportunity to participate in the CDP
Europe event as part of our ongoing commitment to being at the
forefront of novel cannabinoid therapeutics and novel means of
manufacturing them," remarked Eric A.
Adams, President and Chief Executive Officer of InMed.
"InMed has made important strides in both its therapeutic
development and manufacturing programs over the past year and that
has reinforced our position as a leading innovator to speak on
these key topics."
For more information on the conference, please visit
https://cdp-europe.com/.
About InMed: InMed Pharmaceuticals is a clinical-stage
pharmaceutical company developing a pipeline of cannabinoid-based
medications, initially focused on the therapeutic benefits of
cannabinol ("CBN") in diseases with high unmet medical need. The
Company is dedicated to delivering new therapeutic alternatives to
patients that may benefit from cannabinoid-based medicines. For
more information, visit www.inmedpharma.com.
Cautionary Note Regarding Forward-Looking
Information:
This news release contains "forward-looking information" and
"forward-looking statements" (collectively, "forward-looking
information") within the meaning of applicable securities laws.
Forward-looking information is based on management's current
expectations and beliefs and is subject to a number of risks and
uncertainties that could cause actual results to differ materially
from those described in the forward-looking statements.
Forward-looking information in this news release includes
statements about: presenting at the 2021 Cannabinoid-Derived
Pharmaceuticals Industry Review Summit Europe; leading the way in
the clinical development of cannabinol (CBN); developing a pipeline
of cannabinoid-based medications in diseases with high unmet
medical need; and delivering new therapeutic alternatives to
patients that may benefit from cannabinoid-based medicines.
All forward-looking information herein is qualified in its
entirety by this cautionary statement, and InMed disclaims any
obligation to revise or update any such forward-looking information
or to publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by law.
NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS
SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE
ADEQUACY OR ACCURACY OF THIS RELEASE.
View original
content:http://www.prnewswire.com/news-releases/inmed-pharmaceuticals-to-participate-in-2021-cannabinoid-derived-pharmaceuticals-industry-review-summit-europe-301211114.html
SOURCE InMed Pharmaceuticals Inc.